12.93 USD
-0.04 (-0.31%)
12.93 USD
0 (0%)
NVCR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of NVCR have multiple concerns. NVCR is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year NVCR has reported negative net income.
In the past year NVCR has reported a negative cash flow from operations.
NVCR had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: NVCR reported negative operating cash flow in multiple years.
1.2 Ratios
NVCR has a Return On Assets (-13.05%) which is comparable to the rest of the industry.
NVCR has a Return On Equity of -52.05%. This is comparable to the rest of the industry: NVCR outperforms 51.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.05% | ||
| ROE | -52.05% | ||
| ROIC | N/A |
ROA(3y)-13.14%
ROA(5y)-8.53%
ROE(3y)-41.63%
ROE(5y)-26.99%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 75.57%, NVCR belongs to the best of the industry, outperforming 86.63% of the companies in the same industry.
In the last couple of years the Gross Margin of NVCR has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for NVCR so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 75.57% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.51%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
NVCR does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NVCR has more shares outstanding
Compared to 5 years ago, NVCR has more shares outstanding
The debt/assets ratio for NVCR is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -0.02, we must say that NVCR is in the distress zone and has some risk of bankruptcy.
NVCR has a Altman-Z score of -0.02. This is comparable to the rest of the industry: NVCR outperforms 44.92% of its industry peers.
NVCR has a Debt/Equity ratio of 2.21. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 2.21, NVCR is not doing good in the industry: 81.82% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.21 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.02 |
ROIC/WACCN/A
WACC6.49%
2.3 Liquidity
A Current Ratio of 1.55 indicates that NVCR should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.55, NVCR is doing worse than 73.26% of the companies in the same industry.
A Quick Ratio of 1.50 indicates that NVCR should not have too much problems paying its short term obligations.
NVCR has a Quick ratio (1.50) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.55 | ||
| Quick Ratio | 1.5 |
3. Growth
3.1 Past
The earnings per share for NVCR have decreased strongly by -15.00% in the last year.
The Revenue has grown by 11.17% in the past year. This is quite good.
The Revenue has been growing by 11.49% on average over the past years. This is quite good.
EPS 1Y (TTM)-15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.86%
Revenue 1Y (TTM)11.17%
Revenue growth 3Y4.2%
Revenue growth 5Y11.49%
Sales Q2Q%7.81%
3.2 Future
Based on estimates for the next years, NVCR will show a very strong growth in Earnings Per Share. The EPS will grow by 23.02% on average per year.
The Revenue is expected to grow by 19.52% on average over the next years. This is quite good.
EPS Next Y9.53%
EPS Next 2Y1.15%
EPS Next 3Y8.91%
EPS Next 5Y23.02%
Revenue Next Year8.7%
Revenue Next 2Y7.15%
Revenue Next 3Y9.29%
Revenue Next 5Y19.52%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for NVCR. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVCR. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.15%
EPS Next 3Y8.91%
5. Dividend
5.1 Amount
NVCR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
12.93
-0.04 (-0.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners83.34%
Inst Owner Change-2.9%
Ins Owners2.76%
Ins Owner Change0.3%
Market Cap1.45B
Revenue(TTM)642.27M
Net Income(TTM)-177.65M
Analysts81.54
Price Target25.43 (96.67%)
Short Float %6.78%
Short Ratio4.1
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.64%
Min EPS beat(2)8.12%
Max EPS beat(2)23.15%
EPS beat(4)3
Avg EPS beat(4)-2.03%
Min EPS beat(4)-73.92%
Max EPS beat(4)34.54%
EPS beat(8)7
Avg EPS beat(8)8.46%
EPS beat(12)8
Avg EPS beat(12)0.73%
EPS beat(16)10
Avg EPS beat(16)-6.5%
Revenue beat(2)2
Avg Revenue beat(2)1.97%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.98%
Revenue beat(4)4
Avg Revenue beat(4)1.94%
Min Revenue beat(4)0.18%
Max Revenue beat(4)3.65%
Revenue beat(8)7
Avg Revenue beat(8)3.15%
Revenue beat(12)7
Avg Revenue beat(12)1.16%
Revenue beat(16)9
Avg Revenue beat(16)0.67%
PT rev (1m)-7.46%
PT rev (3m)-9.35%
EPS NQ rev (1m)0%
EPS NQ rev (3m)20.19%
EPS NY rev (1m)1.39%
EPS NY rev (3m)12.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)5.52%
Revenue NY rev (1m)0.2%
Revenue NY rev (3m)2.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.25 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.24 | ||
| P/tB | 4.24 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.61
EYN/A
EPS(NY)-1.52
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS5.74
BVpS3.05
TBVpS3.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.05% | ||
| ROE | -52.05% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 75.57% | ||
| FCFM | N/A |
ROA(3y)-13.14%
ROA(5y)-8.53%
ROE(3y)-41.63%
ROE(5y)-26.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.51%
GM growth 5Y0.68%
F-Score2
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.21 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 226.76% | ||
| Cap/Sales | 4.78% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.55 | ||
| Quick Ratio | 1.5 | ||
| Altman-Z | -0.02 |
F-Score2
WACC6.49%
ROIC/WACCN/A
Cap/Depr(3y)276.52%
Cap/Depr(5y)245.8%
Cap/Sales(3y)5.46%
Cap/Sales(5y)4.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-17.86%
EPS Next Y9.53%
EPS Next 2Y1.15%
EPS Next 3Y8.91%
EPS Next 5Y23.02%
Revenue 1Y (TTM)11.17%
Revenue growth 3Y4.2%
Revenue growth 5Y11.49%
Sales Q2Q%7.81%
Revenue Next Year8.7%
Revenue Next 2Y7.15%
Revenue Next 3Y9.29%
Revenue Next 5Y19.52%
EBIT growth 1Y-10.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.16%
EBIT Next 3Y27.38%
EBIT Next 5Y42.57%
FCF growth 1Y26.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.83%
OCF growth 3YN/A
OCF growth 5YN/A
NOVOCURE LTD / NVCR FAQ
What is the fundamental rating for NVCR stock?
ChartMill assigns a fundamental rating of 2 / 10 to NVCR.
What is the valuation status for NVCR stock?
ChartMill assigns a valuation rating of 0 / 10 to NOVOCURE LTD (NVCR). This can be considered as Overvalued.
Can you provide the profitability details for NOVOCURE LTD?
NOVOCURE LTD (NVCR) has a profitability rating of 2 / 10.